Long-term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study

被引:2
作者
Pietila-Effati, Paivi [1 ]
Saarinen, Jukka T. [2 ]
Loyttyniemi, Eliisa [3 ]
Saarenhovi, Maria [4 ]
Autio, Reijo [5 ]
Kantola, Ilkka [6 ]
机构
[1] Vaasa Cent Hosp, Dept Cardiol, Vaasa, Finland
[2] Vaasa Cent Hosp, Dept Neurol, Vaasa, Finland
[3] Univ Turku, Dept Biostat, Turku, Finland
[4] Univ Turku, Turku Univ Hosp, Dept Clin Physiol & Nucl Med, Turku, Finland
[5] Vaasa Cent Hosp, Dept Radiol, Vaasa, Finland
[6] Univ Turku, Turku Univ Hosp, Div Med, Turku, Finland
关键词
efficacy; enzyme replacement therapy; Fabry disease; follow-up study; sex; variant; HEALTH-CARE PROFESSIONALS; HIGHLY SENSITIVE ASSAY; ALPHA-GALACTOSIDASE; AGALSIDASE-BETA; CARDIOVASCULAR OUTCOMES; MAGNETIC-RESONANCE; KIDNEY-FUNCTION; ADULT PATIENTS; HEART; IDENTIFICATION;
D O I
10.1002/ajmg.a.63216
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Fabry disease (FD) is an X chromosome-linked, life-threatening lysosomal disease caused by one of more than 1000 currently known variants in the alpha-galactosidase A (GLA) gene. The follow-up part of the Fabry Disease in Ostrobothnia (FAST) study reports the long-term effect of enzyme replacement therapy (ERT) on a prospectively collected cohort of 12 patients, 4 males and 8 females, mean age 46 years (SD 16), with the classical variant c.679C > T p.Arg227Ter, which is one of the most common FD variants worldwide. In the natural history period of the FAST study, half of the patients in both sexes had at least one major event, of which 80% were of cardiac origin. During 5 years of ERT, four patients had a total of six major clinical events consisting of one silent ischemic stroke, three ventricular tachycardias and two increased left ventricular mass indexes. In addition, four patients developed minor cardiac events, four patients minor renal events, and one patient a minor neurological event. ERTs may delay but not prevent the progression of the disease in most patients with the variant Arg227Ter. This variant might be suitable for investigating the efficacy of second-generation ERTs compared to the currently used ERTs regardless of sex.
引用
收藏
页码:1858 / 1869
页数:12
相关论文
共 64 条
[1]   Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: The multi-ethnic study of atherosclerosis [J].
Al Rifai, Mahmoud ;
Yao, Jie ;
Guo, Xiuqing ;
Post, Wendy S. ;
Malik, Shaista ;
Blumenthal, Roger S. ;
Ballantyne, Christie M. ;
Budoff, Matthew ;
Taylor, Kent D. ;
Linb, Henry J. ;
Rich, Stephen S. ;
Hajek, Catherine ;
Greenland, Philip ;
Rotter, Jerome I. ;
Virani, Salim S. .
PROGRESS IN CARDIOVASCULAR DISEASES, 2022, 74 :19-27
[2]  
[Anonymous], 15 ANN WORLD S ORL F
[3]   Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study [J].
Arends, Maarten ;
Biegstraaten, Marieke ;
Wanner, Christoph ;
Sirrs, Sandra ;
Mehta, Atul ;
Elliott, Perry M. ;
Oder, Daniel ;
Watkinson, Oliver T. ;
Bichet, Daniel G. ;
Khan, Aneal ;
Iwanochko, Mark ;
Vaz, Frederic M. ;
van Kuilenburg, Andre B. P. ;
West, Michael L. ;
Hughes, Derralynn A. ;
Hollak, Carla E. M. .
JOURNAL OF MEDICAL GENETICS, 2018, 55 (05) :351-358
[4]   Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors [J].
Arends, Maarten ;
Biegstraaten, Marieke ;
Hughes, Derralynn A. ;
Mehta, Atul ;
Elliott, Perry M. ;
Oder, Daniel ;
Watkinson, Oliver T. ;
Vaz, Frederic M. ;
van Kuilenburg, Andre A. B. P. ;
Wanner, Christoph ;
Hollak, Carla E. M. .
PLOS ONE, 2017, 12 (08)
[5]   Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease [J].
Arends, Maarten ;
Wijburg, Frits A. ;
Wanner, Christoph ;
Vaz, Frederic M. ;
van Kuilenburg, Andre B. P. ;
Hughes, Derralynn A. ;
Biegstraaten, Marieke ;
Mehta, Atul ;
Hollak, Carla E. M. ;
Langeveld, Mirjam .
MOLECULAR GENETICS AND METABOLISM, 2017, 121 (02) :157-161
[6]   Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study [J].
Arends, Maarten ;
Wanner, Christoph ;
Hughes, Derralynn ;
Mehta, Atul ;
Oder, Daniel ;
Watkinson, Oliver T. ;
Elliott, Perry M. ;
Linthorst, Gabor E. ;
Wijburg, Frits A. ;
Biegstraaten, Marieke ;
Hollak, Carla E. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (05) :1631-1641
[7]   LV Mass Assessed by Echocardiography and CMR, Cardiovascular Outcomes, and Medical Practice [J].
Armstrong, Anderson C. ;
Gidding, Samuel ;
Gjesdal, Ola ;
Wu, Colin ;
Bluemke, David A. ;
Lima, Joao A. C. .
JACC-CARDIOVASCULAR IMAGING, 2012, 5 (08) :837-848
[8]   The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat [J].
Benjamin, Elfrida R. ;
Della Valle, Maria Cecilia ;
Wu, Xiaoyang ;
Katz, Evan ;
Pruthi, Farhana ;
Bond, Sarah ;
Bronfin, Benjamin ;
Williams, Hadis ;
Yu, Julie ;
Bichet, Daniel G. ;
Germain, Dominique P. ;
Giugliani, Roberto ;
Hughes, Derralynn ;
Schiffmann, Raphael ;
Wilcox, William R. ;
Desnick, Robert J. ;
Kirk, John ;
Barth, Jay ;
Barlow, Carrolee ;
Valenzano, Kenneth J. ;
Castelli, Jeff ;
Lockhart, David J. .
GENETICS IN MEDICINE, 2017, 19 (04) :430-438
[9]   ENZYMATIC DEFECT IN FABRYS DISEASE - CERAMIDETRIHEXOSIDASE DEFICIENCY [J].
BRADY, RO ;
GAL, AE ;
BRADLEY, RM ;
MARTENSS.E ;
WARSHAW, AL ;
LASTER, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (21) :1163-&
[10]   Predictors of Clinical Evolution in Prehypertrophic Fabry Disease [J].
Camporeale, Antonia ;
Pieroni, Maurizio ;
Pieruzzi, Federico ;
Lusardi, Paola ;
Pica, Silvia ;
Spada, Marco ;
Mignani, Renzo ;
Burlina, Alessandro ;
Bandera, Francesco ;
Guazzi, Marco ;
Graziani, Francesca ;
Crea, Filippo ;
Greiser, Adreas ;
Boveri, Sara ;
Ambrogi, Federico ;
Lombardi, Massimo .
CIRCULATION-CARDIOVASCULAR IMAGING, 2019, 12 (04) :e008424